Drug Search Results
More Filters [+]

Casopitant

Alternative Names: casopitant, gw679769
Latest Update: 2024-02-01
Latest Update Note: PubMed Publication

Product Description

Casopitant is a novel NK1 receptor antagonist and second in the class of antiemetics that acts to antagonise the emetogenic effect of substance P. Casopitant has now completed phase III trials for prevention of CINV.  (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697542/)

Mechanisms of Action: NK1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Casopitant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Oncology Unspecified|Colorectal Cancer|Other|Lung Cancer

Phase 2: Depressive Disorder, Major|Insomnia|Anesthesia Related|Urinary Incontinence|Enuresis|Fibromyalgia|Other|Oncology Unspecified|Overactive Bladder|Spinal Cord Injuries|Dyspepsia

Phase 1: Healthy Volunteers|Phobia, Social|Oncology Unspecified|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00891761

P3

Withdrawn

Lung Cancer

2010-07-01

NKV110721

P3

Completed

Colorectal Cancer

2009-04-13

2007-005169-36

P3

Completed

Colorectal Cancer

2009-04-07

NKT102783

P1

Completed

Kidney Diseases

2008-08-22

Recent News Events